Managed Account Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Managed Account Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$904K	Buy	15,492 +1,110	+8%	+$63.5K	﹤0.01%	2137
2015 Q1	$793K	Buy	14,382 +2,463	+21%	+$133K	﹤0.01%	2157
2014 Q4	$598K	Buy	11,919 +1,660	+16%	+$81.2K	﹤0.01%	2169
2014 Q3	$474K	Sell	10,259 -272	-3%	-$12.3K	﹤0.01%	2187
2014 Q2	$460K	Buy	10,531 +4,006	+61%	+$162K	﹤0.01%	2173
2014 Q1	$272K	Buy	6,525 +1,659	+34%	+$71K	﹤0.01%	2200
2013 Q4	$180K	Buy	4,866 +444	+10%	+$15.9K	﹤0.01%	2226
2013 Q3	$155K	Buy	4,422 +1,714	+63%	+$56.8K	﹤0.01%	2176
2013 Q2	$78K	Buy	+2,708	New	+$77K	﹤0.01%	2241

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Managed Account Advisors's PBE Position: Q2 2015 in Review

Managed Account Advisors increased its Invesco Biotechnology & Genome ETF (PBE) stake by 7.7% in Q2 2015, buying an estimated $63.5K and bringing the position to 15,492 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

Managed Account Advisors first reported a position in PBE in Q2 2013 and has held it in 9 quarters since. 86 funds tracked by Wall St. Rank hold PBE as of Q2 2015.

Managed Account Advisors held 15,492 shares of Invesco Biotechnology & Genome ETF worth $904K as of Q2 2015.
Managed Account Advisors bought 1,110 Invesco Biotechnology & Genome ETF shares in Q2 2015, an estimated $63.5K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2137 holding.
Managed Account Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 9 quarters since.
86 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.